

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE
INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT
SOUTHBOUND TRADING LINK

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest development of the Company.

The board (the “**Board**”) of directors of the Company is pleased to announce that, with effect from March 9, 2026, the shares (the “**Shares**”) of the Company will be included (i) as a constituent stock of the Hang Seng Composite Index by Hang Seng Indexes Company Limited and (ii) in the list of eligible shares of the Stock Connect Southbound Trading Link.

The inclusion of the Shares as eligible securities under the Hang Seng Composite Index and the Stock Connect Southbound Trading Link represents the capital market's high recognition of the Company's performance and value and allows eligible investors in mainland China to directly invest in the Shares listed on The Stock Exchange of Hong Kong Limited through the Shanghai Hong Kong Stock Connect and Shenzhen Hong Kong Stock Connect mechanisms. It is expected that the inclusion will further expand the Company's investor base, increase the trading liquidity for the Shares, and further optimize the shareholder structure.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and
Chief Executive Officer

Hong Kong, March 6, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.